Marie Nöelle Delyfer

Prof. Marie Nöelle Delyfer

1. Professor of Ophthalmology, Medical and Surgical Retina Unit, Ophthalmology Department, Bordeaux University Hospital, Bordeaux, France
+1
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
Marie Nöelle DelyferMarie Nöelle Delyfer
Marie Nöelle Delyfer
MRMarie-Bénédicte Rougier
Marie-Bénédicte Rougier
SLSandy Leoni
Sandy Leoni
QZQiuhua Zhang
Qiuhua Zhang
FDFrancis Dalbon
Francis Dalbon
JKJean-François Korobelnik
Jean-François Korobelnik
To report cases of intraocular inflammation after intracameral injection of a very high dose of cefuroxime at the end of uneventful cataract surgery. Department of Ophthalmology, Bordeaux University Hospital, Bordeaux, France. Case series. Patients were followed on an outpatient basis and were examined postoperatively at 1 and 5 days and 6 weeks. Central macular thickness, angiography, central corneal thickness (CCT), endothelial cell density (ECD), and electroretinography (ERG) were analyzed to evaluate ocular toxicity. One day postoperatively, the mean corrected distance visual acuity (CDVA) was 0.95 logMAR ± 0.40 (SD). All the cases had moderate anterior inflammation. Retinal optical coherence tomography scans systematically showed extensive macular edema (mean 843.2 ± 212.7 μm) associated with a large serous retinal detachment. Fluorescein angiograms showed diffuse leakage without abnormal retinal perfusion. At 5 days, the mean CDVA improved significantly to 0.52 ± 0.29 logMAR (P < .005), as did the macular edema and serous retinal detachment (mean 339.4 ± 138.3 μm) (P = .005). At 6 weeks, the mean CDVA reached 0.09 ± 0.06 logMAR. Modifications in CCT and ECD were similar to those observed after uneventful phacoemulsification. The macular thickness (mean 288.4 ± 22.6 μm) and profile returned to normal in all patients, although ERG recordings showed reduced rod photoreceptor cell function (P < .05). Intracameral injection of high doses of cefuroxime induced anterior and posterior inflammation. Without surgical intervention, the final visual outcome was satisfactory in all cases. Long-term retinal function, however, must be assessed through repeated ERG recordings.

1 March 2012 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
Marie Nöelle DelyferMarie Nöelle Delyfer
Marie Nöelle Delyfer
BBBenjamin Buaud
Benjamin Buaud
JKJean-François Korobelnik
Jean-François Korobelnik
MRMarie-Bénédicte Rougier
Marie-Bénédicte Rougier
WSWolfgang Schalch
Wolfgang Schalch
CDCécile Delcourt
Cécile Delcourt
Purpose.: To assess the correlation between macular pigment optical density and plasma levels of lutein, zeaxanthin, and fatty acids, especially omega-3 polyunsaturated fatty acids (PUFAs). Methods.: The PIMAVOSA study is an observational study of 107 healthy volunteers, aged 20 to 60 years and born in southwest France, without histories of ocular disease. Macular pigment optical density (MPOD) was measured using the two-wavelength autofluorescence method with a modified scanning laser ophthalmoscope. Plasma measurements (lutein, zeaxanthin, and fatty acids) were performed from fasting blood samples collected on the day of the eye examination. Results.: MPOD within 6° correlated with plasma levels of lutein and zeaxanthin (r = 0.35, P < 0.001, and r = 0.30, P < 0.005, respectively). MPOD also significantly correlated with total plasma omega-3 PUFAs (r = 0.22, P < 0.05). Among the different omega-3 PUFAs, docosapentaenoic acid (DPA) had the highest correlation with MPOD (r = 0.31, P < 0.001), whereas correlation with eicosapentaenoic acid (EPA) was moderate (r = 0.21, P < 0.05) and did not reach statistical significance for docosahexaenoic acid (r = 0.14, P = 0.14). Conclusions.: In the present study, macular pigment density was associated not only with plasma lutein and zeaxanthin but also with omega-3 long-chain PUFAs, particularly with EPA and DPA. Further studies will be needed to confirm these findings and to identify the underlying mechanisms.

15 June 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
BMBénédicte MJ Merle
Bénédicte MJ Merle
ACAudrey Cougnard-Grégoire
Audrey Cougnard-Grégoire
JKJean-François Korobelnik
Jean-François Korobelnik
WSWolfgang Schalch
Wolfgang Schalch
SEStéphane Etheve
Stéphane Etheve
CDCécile Delcourt
Cécile Delcourt
Lutein and zeaxanthin may lower the risk of age-related macular degeneration (AMD). We evaluated the associations of plasma lutein and zeaxanthin with the incidence of advanced AMD in the Alienor study (Antioxydants Lipides Essentiels Nutrition et Maladies Oculaires). Alienor study is a prospective population-based cohort of 963 residents of Bordeaux, France, who were 73 years or older at baseline (2006–2008). The present study included 609 participants with complete ophthalmologic and plasma carotenoids data. Examinations were performed every two years over an eight-year period (2006 to 2017). Plasma lutein and zeaxanthin were determined at baseline from fasting blood samples using high-performance liquid chromatography. Cox proportional hazard models were used to assess associations between plasma lutein, zeaxanthin, and their (total cholesterol (TC) + triglycerides (TG)) ratios with AMD. Among the 609 included participants, 54 developed advanced incident AMD during a median follow-up time of 7.6 years (range 0.7 to 10.4). Participants with higher plasma lutein had a reduced risk for incident advanced AMD in the fully adjusted model (HR = 0.63 per 1-SD increase (95% CI, 0.41–0.97), p = 0.03). A similar association was observed using the lutein/(TC + TG) ratio (HR = 0.59 (95% CI, 0.39–0.90), p = 0.01). No associations were evidenced for other carotenoids. Higher plasma lutein was associated with a 37% reduced risk of incident advanced AMD.

7 January 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Laurent KodjikianLaurent Kodjikian
Laurent Kodjikian
Stéphanie BAILLIFStéphanie BAILLIF
Stéphanie BAILLIF
CCCatherine Creuzot-Garcher
Catherine Creuzot-Garcher
Marie Nöelle DelyferMarie Nöelle Delyfer
Marie Nöelle Delyfer
FMFREDERIC MATONTI
FREDERIC MATONTI
Thibaud MathisThibaud Mathis
Thibaud Mathis
To assess real-world outcomes of fluocinolone acetonide (FAc) implant in treating diabetic macular edema (DME), a systematic literature review was conducted on PubMed in order to identify publications assessing the efficacy and safety of the FAc implant in DME in daily practice. Case reports and randomized controlled trials were excluded. Twenty-two observational real-world studies analyzing a total of 1880 eyes were included. Mean peak visual gain was +8.7 letters (11.3 months post-FAc injection) and was greater for lower baseline best corrected visual acuity (BCVA) and for more recent DME. Mean central retinal thickness (CRT) decreased 34.3% from baseline. 77.0% of the analyzed studies reported both BCVA improvement of at least five letters and a CRT decrease by 20% or more. Rescue therapy was needed more frequently when FAc was administered for chronic DME. FAc-induced ocular hypertension was reported in 20.1% of patients but only 0.6% needed surgery. Cataract extraction was performed in 43.2% of phakic patients. Adequate patient selection is essential for optimal FAc response and better safety profile. Currently positioned as second- or third-line treatment in the management algorithm, FAc implant decreases treatment burden and provides better letter gain when administered for more recent DME.

17 April 2020 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
Marie Nöelle DelyferMarie Nöelle Delyfer
Marie Nöelle Delyfer
PLPierre Legout
Pierre Legout
MGMélanie Le Goff
Mélanie Le Goff
MBMarion Blaizeau
Marion Blaizeau
MRMarie‐Bénédicte Rougier
Marie‐Bénédicte Rougier
CDCécile Delcourt
Cécile Delcourt

1 May 2020 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
CDCyril Dutheil
Cyril Dutheil
MGMélanie Le Goff
Mélanie Le Goff
ACAudrey Cougnard-Grégoire
Audrey Cougnard-Grégoire
SGSarra Gattoussi
Sarra Gattoussi
JKJean-François Korobelnik
Jean-François Korobelnik
Marie Nöelle DelyferMarie Nöelle Delyfer
Marie Nöelle Delyfer
Age-related macular degeneration (AMD) is the third most common cause of visual impairment worldwide, and the number of people with AMD is expected to increase by approximately 40% between 2020 and 2040.1 Early AMD is clinically characterized by the presence of yellowish drusen,2 which are accumulations of extracellular material between the retinal pigment epithelium–basal lamina and the inner collagenous layer of the Bruch membrane. A specific category of drusen called reticular pseudodrusen (RPD),3 or subretinal drusenoid deposits,4 corresponds to drusen-like, granular hyperreflective material located not beneath but above the retinal pigment epithelium.5 Early identification of RPD is important because they have been shown to be a major risk factor of advanced AMD, compared with other drusen,6 with a cumulative incidence risk ranging from 33.9% to 54.5% at 5 years.7,8